0000914190-20-000237.txt : 20200708
0000914190-20-000237.hdr.sgml : 20200708
20200708174743
ACCESSION NUMBER: 0000914190-20-000237
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200706
FILED AS OF DATE: 20200708
DATE AS OF CHANGE: 20200708
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hippel James
CENTRAL INDEX KEY: 0001603594
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-17272
FILM NUMBER: 201019090
MAIL ADDRESS:
STREET 1: 614 MCKINLEY PLACE NE
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55413
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIO-TECHNE Corp
CENTRAL INDEX KEY: 0000842023
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 411427402
STATE OF INCORPORATION: MN
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 614 MCKINLEY PL N E
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55413
BUSINESS PHONE: 6123798854
MAIL ADDRESS:
STREET 1: 614 MCKINLEY PLACE NE
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55413
FORMER COMPANY:
FORMER CONFORMED NAME: TECHNE CORP /MN/
DATE OF NAME CHANGE: 19920703
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2020-07-06
0000842023
BIO-TECHNE Corp
TECH
0001603594
Hippel James
614 MCKINLEY PLACE N.E.
MINNEAPOLIS
MN
55413
0
1
0
0
Chief Financial Officer
Common Stock
2020-07-06
4
M
0
21502
108.49
A
30809
D
Common Stock
2020-07-06
4
S
0
9571
270.4532
D
21238
D
Common Stock
2020-07-06
4
S
0
3781
271.5333
D
17457
D
Common Stock
2020-07-06
4
S
0
4947
272.338
D
12510
D
Common Stock
2020-07-06
4
S
0
1934
273.7115
D
10576
D
Common Stock
2020-07-06
4
S
0
1269
274.5177
D
9307
D
Common Stock
2020-07-07
4
M
0
2577
108.49
A
11884
D
Common Stock
2020-07-07
4
S
0
414
270.5567
D
11470
D
Common Stock
2020-07-07
4
S
0
1663
271.4019
D
9807
D
Common Stock
2020-07-07
4
S
0
500
272.26
D
9307
D
Stock Options (Right to Buy)
108.49
2020-07-06
4
M
0
21502
0
D
2022-08-07
Common Stock
21502
18486
D
Stock Options (Right to Buy)
108.49
2020-07-07
4
M
0
2577
0
D
2022-08-07
Common Stock
2577
15909
D
Stock Options (Right to Buy)
106.59
2023-08-18
Common Stock
30400
30400
D
Stock Options (Right to Buy)
106.59
2023-08-18
Common Stock
40533
40533
D
Restricted Stock Units
Common Stock
4438
4438
D
Stock Options (Right to Buy)
125.05
2024-08-09
Common Stock
24460
24460
D
Stock Options (Right to Buy)
125.05
2024-08-09
Common Stock
32613
32613
D
Restricted Stock Units
Common Stock
3383
3383
D
Stock Options (Right to Buy)
177.32
2025-08-08
Common Stock
18066
18066
D
Stock Options (Right to Buy)
177.32
2025-08-08
Common Stock
24089
24089
D
Restricted Stock Units
Common Stock
3938
3938
D
Stock Options (Right to Buy)
190.41
2026-08-07
Common Stock
19936
19936
D
Stock Options (Right to Buy)
190.41
2026-08-07
Common Stock
26581
26581
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.0000 to $270.9800, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.0000 to $271.9900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.0100 to $272.9500, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.2300 to $274.2200, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.2700 to $275.0300, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.0700 to $271.0500, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.0700 to $271.9000, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.0900 to $272.3500, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
Fully exercisable.
Options to purchase 10,134 shares vest on 8/18/2017 and options to purchase 10,133 shares vest on each of 8/18/2018, 8/18/2019 and 8/18/2020.
Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Options to purchase 8,153 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and options to purchase 8,154 shares vest on 8/9/2021.
Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Options to purchase 6,023 shares vest on 8/8/2019 and options to purchase 6,022 shares vest on each of 8/8/2020, 8/8/2021 and 8/8/2022.
Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Options to purchase 6,646 shares vest on 8/7/2020 and options to purchase 6,645 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.
/s/ Brenda S. Furlow, Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed.
2020-07-08